 SAN DIEGO, Dec. 09, 2022 GLOBE NEWSWIRE Erasca, Inc. Nasdaq: ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of 6.50 per share. All of ... The post Erasca Announces Pricing of Underwritten Offering of Common Stock appeared first on ForexTV... 